Skip to content
Marker Therapeutics, Inc.
Marker Therapeutics, Inc.
  • About
    • Overview
    • Company Management
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Multi Antigen Targeted T Cell Therapies
    • T Cell Vaccines
    • PolyStart™
  • Clinical Studies
    • Pipeline
    • MultiTAA T Cell Therapy
    • TPIV200
    • TPIV100/110
  • Investors
    • Overview
    • Briefcase
    • Stock Information
    • Financial Filings
    • Research Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Email Alerts
  • News & Media
    • Press Releases
    • Media Coverage
    • Event Calendar
    • Press Kit / Media
  • Careers
  • Contact
  • About
    • Overview
    • Company Management
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Multi Antigen Targeted T Cell Therapies
    • T Cell Vaccines
    • PolyStart™
  • Clinical Studies
    • Pipeline
    • MultiTAA T Cell Therapy
    • TPIV200
    • TPIV100/110
  • Investors
    • Overview
    • Briefcase
    • Stock Information
    • Financial Filings
    • Research Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Email Alerts
  • News & Media
    • Press Releases
    • Media Coverage
    • Event Calendar
    • Press Kit / Media
  • Careers
  • Contact

Daily Archives: October 10, 2018

You are here:
  1. Home
  2. 2018
  3. October
  4. 10

TapImmune’s HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

Featured, Press ReleasesBy Aaron SantosOctober 10, 2018

Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment.

SIGN UP FOR EMAIL ALERTS

Get Marker News Delivered To Your Inbox

Sign Up Today

Join the MRKR VIP List